When a medical device reaches a patient in Munich, São Paulo, or Tokyo, the Instructions for Use that accompany it must be flawlessly localized, not merely translated. A single ambiguous warning, a misaligned symbol, or a non-compliant electronic IFU can trigger regulatory rejection, product recalls, or patient harm. Under the EU Medical Devices Regulation (MDR 2017/745) and the In Vitro Diagnostic Regulation (IVDR 2017/746), manufacturers must provide IFUs in the official language of every member state where the device is placed on the market. The FDA imposes its own labeling requirements tied to the Unique Device Identification (UDI) system. This guide walks through the regulatory landscape, the end-to-end localization workflow, and the systems integration needed to build a compliant, scalable IFU localization process, and explains where Ollang fits as the execution layer.
For a practical walkthrough of how this workflow is executed at scale, see Ollang in action: See Ollang in action
Regulatory Framework for IFU and eIFU Localization
MDR and IVDR Language Requirements
The EU MDR (Article 10(11)) and IVDR require that all information supplied with a device, including the IFU, be provided in the official language(s) determined by the member state where the device is made available. This is not a recommendation; it is a condition of CE marking. Notified bodies routinely audit language coverage during conformity assessment, and national competent authorities can pull devices from the market if IFUs are missing or linguistically deficient.
For manufacturers selling across the EU, this means supporting up to 24 official languages. Each language version must be identical in meaning and completeness to the source IFU. Partial translations, summarized content, or machine-translated text that has not been reviewed by qualified linguists does not satisfy the regulation. The MDR also requires that the information be "understood by the intended user," which introduces readability and comprehension as regulatory criteria, not just linguistic accuracy.
FDA UDI and Labeling Obligations
In the United States, the FDA's UDI system (21 CFR Part 801) requires that device labels and labeling, including IFUs, carry specific identifiers and comply with labeling regulations. While the FDA does not mandate translation into languages other than English for domestic distribution, any labeling provided in another language must be accurate and consistent with the English-language version. For devices distributed internationally through FDA-cleared pathways, manufacturers must ensure that localized IFUs align with the cleared labeling content.
The UDI rule also requires that certain data elements be submitted to the Global Unique Device Identification Database (GUDID). When IFU content changes during localization, for instance, when a country-specific variant adds or removes indications, the manufacturer must evaluate whether those changes affect the GUDID record or require a new submission.
ISO 15223-1 Symbols and Harmonized Standards
ISO 15223-1 specifies graphical symbols for use in medical device labeling, including IFUs. These symbols, such as "Do not re-use," "Use-by date," and "Manufacturer", are designed to be language-independent, but they must be used correctly and consistently across all localized versions. The standard requires that if a symbol is not expected to be recognized by the user, it must be accompanied by explanatory text, which itself must be localized.
Harmonized standards like EN ISO 20417 (medical devices, information to be supplied by the manufacturer) further specify what content must appear in the IFU and how it should be structured. Localization teams need to work from these standards as their content checklist, ensuring that no required element is dropped, reordered, or altered in a way that changes its regulatory meaning during translation.
Designing the IFU/eIFU Localization Workflow
Building a compliant IFU localization process requires more than assigning files to translators. It demands controlled inputs, qualified human review, regulatory signoff, and auditable outputs at every stage.
If you are evaluating how to structure this workflow for your organization, explore how Ollang's localization platform handles medical device documentation across the full cycle described below.
Controlled Terminology and Source Preparation
The localization workflow begins well before translation. Source IFUs must be authored with controlled terminology, a defined set of approved terms for anatomical references, device components, procedural steps, warnings, and contraindications. This controlled vocabulary serves two purposes: it reduces ambiguity for translators and it enables translation memory systems to deliver consistent matches across product lines and revisions.
Source preparation also includes:
- Tagging all regulatory-critical content (warnings, precautions, contraindications) so translators and reviewers know which segments carry the highest risk
- Separating localizable text from fixed elements like symbols, part numbers, and UDI barcodes
- Validating that the source document conforms to the latest version of the applicable harmonized standard before sending it for translation
Terminology databases should be maintained centrally and version-controlled. When a term changes, for example, when a regulatory authority issues updated guidance on how to describe a particular risk, that change must propagate across all language versions in the next revision cycle.
Machine Translation with Medical Domain Adaptation
Modern IFU localization workflows increasingly use machine translation (MT) as a first-pass productivity tool, but only when the MT engine has been adapted to the medical device domain. General-purpose MT engines produce output that is often dangerously wrong for medical content, confusing "indication" with "contraindication," mistranslating dosage units, or generating grammatically correct but clinically meaningless instructions.
Domain-adapted MT engines are trained or fine-tuned on corpora of previously approved medical device translations, regulatory texts, and clinical documentation. The output from these engines still requires full human post-editing by qualified medical linguists, but the productivity gain is significant: translators spend less time drafting and more time refining accuracy, which compresses cycle times without compromising safety.
The key constraint is traceability. Every MT-generated segment must be flagged in the translation environment so that reviewers know it originated from an engine, and the post-edited version must be stored as the approved translation, not the raw MT output.
Bilingual Linguistic Quality Assurance by Qualified Medical Linguists
Linguistic quality assurance (LQA) for medical device IFUs is not a generic proofreading step. It requires bilingual reviewers who have subject-matter expertise in the relevant medical domain, orthopedics, diagnostics, cardiology, or whatever the device category demands. These reviewers evaluate the translation against the source for:
- Accuracy: Does the target text convey the identical clinical meaning?
- Completeness: Are all warnings, precautions, and procedural steps present?
- Terminology consistency: Does the translation use the approved terms from the controlled terminology database?
- Readability: Can the intended user, who may be a clinician, a lab technician, or a patient, understand the instructions without ambiguity?
- Regulatory compliance: Do localized versions comply with country-specific labeling requirements (e.g., specific phrasing mandated by a national competent authority)?
Reviewer qualifications must be documented and retained as part of the audit pack. Under MDR, notified bodies may request evidence that the individuals who reviewed a translation have the appropriate linguistic and domain credentials.
Regulatory Affairs Signoff and Approval Routing
After LQA, the localized IFU enters a regulatory affairs (RA) review and signoff stage. RA reviewers verify that the translated document aligns with the device's technical documentation, the Declaration of Conformity, and any country-specific regulatory conditions. They confirm that:
- The IFU version number, revision date, and device identifiers are correct
- Country-specific content (e.g., local authorized representative details, import license numbers) has been inserted accurately
- The content is consistent with what was submitted to or approved by the relevant regulatory authority
Approval routing should be electronic, timestamped, and role-based. Each signoff must capture who approved, when, and against which version of the source document. This audit trail is not optional, it is a regulatory expectation under both MDR and FDA quality system regulations (21 CFR Part 820).
Accessibility: PDF/UA and eIFU Compliance
The shift toward electronic IFUs (eIFUs), permitted under EU Regulation 2021/2226 for certain device classes, introduces accessibility requirements. eIFUs must be available on a website that is accessible to persons with disabilities, which means the underlying PDF documents should conform to the PDF/UA (ISO 14289-1) standard.
PDF/UA compliance requires:
- Proper document structure tags (headings, lists, tables, figures with alt text)
- A logical reading order that assistive technologies can follow
- Unicode-compliant text (no text rendered as images)
- Language metadata embedded in the document so screen readers switch languages correctly in multilingual files
For localized eIFUs, this means the localization workflow must produce tagged, accessible PDFs, not flat image-based files. The formatting and tagging step should be validated as part of the QA process, not treated as an afterthought.
Audit Packs: Change Logs, Reviewer Credentials, and Approvals
Every localized IFU must be accompanied by an audit pack that provides a complete traceability record. A well-structured audit pack includes:
| Component | Purpose |
|---|---|
| Change log | Documents every revision, including what changed, why, and who authorized it |
| Reviewer credentials | Confirms qualifications of translators and LQA reviewers (language pair, domain expertise, certifications) |
| Approval records | Timestamped signoffs from LQA reviewers and RA personnel |
| Translation memory snapshots | Records the state of the TM at the time of translation for reproducibility |
| MT disclosure | Flags segments where machine translation was used and confirms post-editing was completed |
These audit packs must be retained for the lifetime of the device plus the period specified by the applicable regulation (typically at least 10 years under MDR for most devices, and 15 years for implantable devices). They should be stored in a system that supports retrieval by device, language, version, and date.